Mouse GFAP ELISA Kit (RMEK-0153753)
Cat. No.: RMEK-0153753
Category: ELISA Kits
INQUIRY
1 x 96 tests
Mouse GFAP ELISA Kit is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of GFAP protein in tissue extracts. The technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our plates. This approach to sandwich ELISA allows the formation of the antibody-analyte sandwich complex in a single step, significantly reducing assay time.
Product Features
| Species Reactivity | Mouse |
|---|---|
| Detection Method | Colorimetric |
| Assay Duration | One step assay |
| Assay Time | 1.5 h |
| Assay Type | Sandwich (quantitative) |
| Precision | Intra-Assay-Tissue-8-4.4%; Inter-Assay-Tissue-3-5.8% |
| Sensitivity | 8.7 pg/mL |
| Range | 125 pg/mL - 8000 pg/mL |
| Sample Type | Tissue Extracts |
| Recovery | Tissue Extracts-97-95% - 100% |
| Key Features | One-wash 90 minute protocol; Sensitivity: 8.7 pg/mL; Range: 125 pg/mL - 8000 pg/mL; Sample type: Tissue Extracts; Detection method: Colorimetric; Assay type: Sandwich (quantitative); Reacts with: Mouse |
Target Information
| Target Symbol | GFAP |
|---|---|
| UniProt ID | P14136 |
| Biomarker of SCs/CSCs | Neural Stem Cells (NSCs) Characterization |
| Function | GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells. |
| Cellular Localization | Cytoplasm. Associated with intermediate filaments. |
| Post-transcriptional Modifications | Phosphorylated by PKN1. |
| Involvement in Disease | Defects in GFAP are a cause of Alexander disease (ALEXD). Alexander disease is a rare disorder of the central nervous system. It is a progressive leukoencephalopathy whose hallmark is the widespread accumulation of Rosenthal fibers which are cytoplasmic inclusions in astrocytes. The most common form affects infants and young children, and is characterized by progressive failure of central myelination, usually leading to death usually within the first decade. Infants with Alexander disease develop a leukoencephalopathy with macrocephaly, seizures, and psychomotor retardation. Patients with juvenile or adult forms typically experience ataxia, bulbar signs and spasticity, and a more slowly progressive course. |
Storage & Shipping
| Storage | Store at 2-8°C |
|---|---|
| Shipping | Gel Packs |
| Stability | The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. |
For research use only. Not for clinical use.
